Genmab — September 2017
-
Så du tror stadig på de 1440 i morgen, Bibob?
-
-
Wuhu!
-
DARA significantly increased the overall survival (OS) and reduced organ infiltration of tumor cells both in MCL and FL systemic xenograft models. In addition, the combination of DARA to Rituximab/CHOP regimen in FL resulted in a synergistic reduction of tumor growth
-
Bibob trykker på købsknappen i morgen eftermiddag. Det var 1.445 i luk, så feriepengene rækker nok ikke helt, meeen konen spæder gerne lidt til.
-
-
Jeg skal ikke ind i Genmab lige foreløbig. Prøver lykken i Gomspace. Det har været en god forretning indtil videre
Tjek link: http://www.euroinvestor.dk/boerser/nasdaq-omx-stockholm/gomspace-group-ab/264448 -
Nedad, helst pænt meget, så vi kan få sorteret alle de utålmodige fra og dem der ikke forstår casens sindssyge potentiale.........Europa's største medicinalkoncern, verdens førende powerhouse, paradigmeskift med Dara og sidst men ikke mindst hvor er mine sokker? Og hvorfor falder kursen?
-
@Mcjean - har du taget dobbelt dosis DARA i dag? Pas på bivirkningerne, de kan give tømmermænd i morgen
-
AB har snart udsolgt.
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind